Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 9, Issue 2, Pages 211-228Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.9.2.211
Keywords
androgen deprivation; antiandrogen; combined androgen blockade; hormonal therapy; intermittant androgen deprivation; luteinizing hormone releasing hormone; prostate cancer; side effect
Categories
Ask authors/readers for more resources
Androgen deprivation continues to play a crucial role in the treatment of advanced and metastatic prostate cancer. In the 65 years since its use was first described, urologists and medical oncologists have developed new and innovative ways to manipulate the hypothalamic-pituitary-gonadal axis with the goal of alleviating symptoms and prolonging the life of men with prostate cancer. Despite the successes that androgen deprivation therapy has brought, each method and regimen possesses unique benefits and burdens, of which the clinician and patient must be cognizant. This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgen deprivation therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available